RECRUITING

Celecoxib for ENT Pain Management

Talk to us

Conditions

Parotidectomy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to find out whether pain can be managed after an operation with celecoxib instead of oxycodone. The main question it aims to answer is if use of celecoxib plus Tylenol reduces the need for oxycodone. Researchers will compare the combination of celecoxib and Tylenol to a placebo to find out whether celecoxib works to manage pain. Participants will: * Take celecoxib, or a placebo, plus Tylenol with opioids as needed * Keep a diary of their pain between visits * Complete questionnaires

Official Title

Celecoxib Pain Management Following Superficial Parotidectomy: Opioid Sparing Protocol

Quick Facts

Study Start:2025-02-28
Study Completion:2026-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06505187

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ability to understand and the willingness to sign a written informed consent document
  2. * Willing to comply with all study procedures and be available for the duration of the study
  3. * Ability to take oral medication
  4. * Undergoing superficial parotidectomy
  5. * Individuals at least 18 years of age
  6. * Adequate organ function as indicated by standard laboratory tests: hematology (complete blood count), clinical chemistry
  1. * History of NSAIDs contraindication (severe congestive heart failure, CABG within 14 days, arrhythmias, significant coronary artery disease, cardiomyopathy, severe hepatic impairment, history of peptic ulcer disease or GI bleeding, use of anticoagulation (other than prophylactic aspirin)
  2. * History of uncontrolled hypertension, cerebrovascular accident, sulfa allergy, allergy to celecoxib
  3. * Concurrent use of CYP2C9 potentiator/inhibitor
  4. * Use of investigational drugs, biologics, or devices within 30 days prior to randomization.
  5. * Individuals who are pregnant, lactating or planning on becoming pregnant during the study.
  6. * Not suitable for study participation due to other reasons at the discretion of the investigators.

Contacts and Locations

Study Contact

Hayley Mann, MD
CONTACT
480-272-4258
hmann3@wisc.edu

Principal Investigator

Tiffany Glazer, MD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

University of Wisconsin
Madison, Wisconsin, 53702
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Tiffany Glazer, MD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-28
Study Completion Date2026-09

Study Record Updates

Study Start Date2025-02-28
Study Completion Date2026-09

Terms related to this study

Additional Relevant MeSH Terms

  • Parotidectomy